肿瘤药学2018，Vol.8Issue(2)：174-178,5.DOI:10.3969/j.issn.2095-1264.2018.02.10
阿帕替尼联合替吉奥治疗晚期胃癌的疗效观察
Efficacy Observation of Apatinib plus S1 for the Treatment of Advanced Gastric Cancer
摘要
Abstract
Objective To evaluate the efficacy, safety and influence of apatinib combined s1 for the treatment of advanced gastric cancer patients. Methods 66 patients with advanced gastric cancer diagnosed by pathology were divided into three groups to receive chemotherapy combine targeted therapy (S1+aptinib), target treatment (aptinib), and best supportive care. Response to therapy was assessed by RECIST criteria 1.1. The clinical follow-up data were investigated for comparison of median progression-free survival (PFS) and overall survival (OS) between different clinicopathologic characteristics. Results All patients were available for evaluation. DCR of advanced gastric cancer could be improved by apatinib. Furthermore, apatinib combined S1 could improve the DCR of paients compared with single apatinib (P<0.05). Efficacy of apatinib was better for AFP positive patients than for AFP negative patients (P<0.05). Conclusion Administration of apatinib combined with S1 in advanced gastric cancer patients was still beneficial in terms of higher disease control rate and better survival, espe-cially in AFP GC.关键词
胃癌/阿帕替尼/替吉奥/化学治疗/靶向治疗Key words
Gastric cancer/Apatinib/S1/Chemotherapy/Target treatment分类
医药卫生引用本文复制引用
马靓,赵霞,钱琦,朱志远,陈平..阿帕替尼联合替吉奥治疗晚期胃癌的疗效观察[J].肿瘤药学,2018,8(2):174-178,5.基金项目
国家自然科学基金(30471702). （30471702）
